Dassen MG, Tree AC, Wiersema L, Neijndorff B, et al. Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2025 Nov 26:S0360-3016(25)06502.
PMID: 41314554